Abbott Laboratories (ABT) Position Decreased by New England Research & Management Inc.

New England Research & Management Inc. decreased its stake in Abbott Laboratories (NYSE:ABT) by 13.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 27,828 shares of the healthcare product maker’s stock after selling 4,398 shares during the quarter. Abbott Laboratories accounts for about 1.6% of New England Research & Management Inc.’s investment portfolio, making the stock its 11th largest holding. New England Research & Management Inc.’s holdings in Abbott Laboratories were worth $2,013,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in ABT. Csenge Advisory Group bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $31,000. Signature Estate & Investment Advisors LLC bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $103,000. Atlantic Trust LLC bought a new position in shares of Abbott Laboratories in the 2nd quarter valued at approximately $104,000. Security National Bank of SO Dak raised its stake in shares of Abbott Laboratories by 72.0% in the 2nd quarter. Security National Bank of SO Dak now owns 2,098 shares of the healthcare product maker’s stock valued at $128,000 after acquiring an additional 878 shares in the last quarter. Finally, Mainstay Capital Management LLC ADV raised its stake in shares of Abbott Laboratories by 1,069.5% in the 2nd quarter. Mainstay Capital Management LLC ADV now owns 4,374 shares of the healthcare product maker’s stock valued at $131,000 after acquiring an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 72.75% of the company’s stock.

A number of research analysts recently weighed in on ABT shares. Cowen raised their price objective on Abbott Laboratories from $72.00 to $86.00 and gave the company an “average” rating in a research note on Friday, October 5th. Zacks Investment Research downgraded Abbott Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Morgan Stanley raised their price objective on Abbott Laboratories from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Wednesday, January 2nd. Goldman Sachs Group raised Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $78.00 to $81.00 in a research report on Friday, November 30th. Finally, Barclays assumed coverage on Abbott Laboratories in a research report on Monday, October 15th. They issued an “overweight” rating and a $80.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $76.86.



In other news, insider Jared Watkin sold 65,000 shares of the business’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $71.00, for a total transaction of $4,615,000.00. Following the completion of the sale, the insider now owns 128,640 shares in the company, valued at $9,133,440. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Miles D. White sold 142,341 shares of the business’s stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $72.35, for a total value of $10,298,371.35. Following the sale, the chairman now owns 3,459,185 shares of the company’s stock, valued at approximately $250,272,034.75. The disclosure for this sale can be found here. Insiders own 0.74% of the company’s stock.

ABT stock traded down $0.35 during trading on Friday, hitting $68.73. The company had a trading volume of 2,044,430 shares, compared to its average volume of 7,140,442. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.42 and a quick ratio of 1.13. The firm has a market cap of $121.96 billion, a price-to-earnings ratio of 27.49, a P/E/G ratio of 1.86 and a beta of 1.24. Abbott Laboratories has a fifty-two week low of $55.58 and a fifty-two week high of $74.92.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 17th. The healthcare product maker reported $0.75 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.75. Abbott Laboratories had a return on equity of 16.05% and a net margin of 2.91%. The business had revenue of $7.66 billion for the quarter, compared to analyst estimates of $7.65 billion. During the same quarter in the previous year, the firm earned $0.66 EPS. Abbott Laboratories’s quarterly revenue was up 12.1% on a year-over-year basis. On average, research analysts anticipate that Abbott Laboratories will post 2.89 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Tuesday, January 15th will be given a $0.32 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.28. The ex-dividend date of this dividend is Monday, January 14th. This represents a $1.28 annualized dividend and a yield of 1.86%. Abbott Laboratories’s payout ratio is presently 44.80%.

WARNING: “Abbott Laboratories (ABT) Position Decreased by New England Research & Management Inc.” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://dakotafinancialnews.com/2019/01/11/abbott-laboratories-abt-position-decreased-by-new-england-research-management-inc.html.

Abbott Laboratories Company Profile

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other.

Featured Story: How Do You Calculate Return on Investment (ROI)?

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply